Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.
The amino terminal region of group A streptococcal M proteins evokes type-specific immunity while the conserved C-repeat epitopes evoke cross-protective immunity against multiple serotypes. The present studies were undertaken to compare the protective efficacy of vaccines containing either type-specific (hexavalent vaccine) or conserved C-repeat (J14 vaccine) M protein epitopes and to determine if combination vaccines resulted in enhanced levels of protection. Our results indicated that the protective efficacy of the type-specific vaccine was significantly greater than that of J14 and that the addition of J14 to vaccine formulations did not enhance the level of protection achieved with type-specific formulations.
Penfound
Thomas A
TA
Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States.
Chiang
Edna Y
EY
Ahmed
Elwaleed A
EA
Dale
James B
JB
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology*; D056738:Cross Protection; D000939:Epitopes / Q000276:immunology; D005260:Female; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D022242:Pneumococcal Vaccines / Q000276:immunology*; D011817:Rabbits; D015610:Serum Bactericidal Test; D013290:Streptococcal Infections / Q000276:immunology / Q000517:prevention & control*; D013297:Streptococcus pyogenes / Q000276:immunology*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D002352:Carrier Proteins; D000939:Epitopes; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; C014689:streptococcal M protein